CJC-1295

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH), engineered as a modified fragment of the first 29 amino acids of GHRH with substitutions that resist enzymatic breakdown ^[1]. Its defining feature is a technology that allows it to bind covalently to endogenous albumin after injection, a drug affinity complex that dramatically extends its circulating half-life to roughly 8 days, hence the long-acting designation ^[2]. Formulations are described both with this albumin-binding modification (with DAC) and without it ^[3].

The compound was developed to overcome a fundamental limitation of native GHRH, whose very short half-life restricts therapeutic use; by prolonging GHRH action, CJC-1295 can sustain stimulation of the pituitary to release growth hormone over an extended period ^[1][2]. In clinical pharmacology studies it was administered subcutaneously to healthy adults to characterize its effects on GH and insulin-like growth factor I (IGF-I) ^[1][2].

Research and applied interest in CJC-1295 spans growth hormone deficiency, body composition, recovery, and, outside approved medicine, physique and performance enhancement ^[3]. It is frequently grouped and stacked with growth hormone secretagogues such as ipamorelin that act through a complementary pathway ^[3]. Regulatory status is investigational; CJC-1295 is not an approved medicine and is sold as a research compound, and it is prohibited in sport, with reviews noting the absence of regulatory approval for performance-related use and the uncertainties of unregulated supply ^[3].

CJC-1295 is a synthetic growth-hormone-releasing hormone (GHRH) analogue that raises growth hormone and IGF-1; it is sold as a research chemical, is not approved for human use, and is prohibited in sport. As a GH secretagogue, class effects include fluid retention and edema, joint pain, carpal tunnel symptoms, insulin resistance and elevated blood glucose, and theoretical acromegaly-type risks with sustained use; injection-site reactions, flushing and headache are also reported.

CJC-1295 was developed by the biotechnology company ConjuChem as a long-acting analogue of growth hormone-releasing hormone, built around a Drug Affinity Complex (DAC) technology that lets the peptide bind covalently to circulating albumin and thereby resist rapid degradation. This design directly addressed the central limitation of native GHRH, whose therapeutic use is constrained by an extremely short duration of action. The pivotal human characterization came in 2005, when Teichman and colleagues reported two randomized, placebo-controlled trials in healthy adults showing that a single subcutaneous dose produced sustained, dose-dependent increases in growth hormone and IGF-I, with an estimated half-life of roughly 5.8 to 8.1 days. Those studies established CJC-1295 as a uniquely long-lasting GHRH analogue and remain the foundation of its use as a research tool for the GH-IGF-I axis.

CJC-1295 is well regarded among researchers studying the growth hormone axis as an elegant demonstration of albumin-binding peptide engineering, prized for delivering days of elevated GH and IGF-I from infrequent dosing. A frequently highlighted strength is that it raises hormone output while preserving the natural pulsatile pattern of GH secretion, which is thought to underlie many of the hormone's physiological effects, rather than flooding the system continuously.

This combination of long action and preserved pulsatility gives it a distinctive appeal relative to native GHRH and short-acting analogues. Balanced discussion notes that its effects depend on intact pituitary secretory capacity and that class-associated effects such as fluid retention, injection-site reactions, and shifts in glucose and other hormones reflect the broad reach of the GH-IGF-I axis; it is best understood as an investigational agent rather than an approved therapy.